Trulieve Cannabis Corp (OP:TCNNF)

11.86 UNCHANGED

Last Price Updated: 7:58 PM EDT, Jul 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Trulieve Cannabis Corp

< Previous 1 2 3 4 5 6 7 8 9

...

44 45 Next >

Better Marijuana Stock to Buy Right Now: Tilray or Trulieve? ↗

June 12, 2026

Trulieve's price has soared this year, while Tilray's has plummeted, but which is the better stock right now?

Via The Motley Fool

Topics Cannabis

The Single Biggest Cannabis Catalyst in Years Is Rapidly Approaching: 2 Marijuana Stocks to Buy Now ↗

June 07, 2026

Two of the top multi-state operators have seen their shares jump since reclassifying news came out, but they may no longer be the best cannabis stocks to buy.

Via The Motley Fool

Topics Cannabis Law Enforcement

Cannabis Stocks Are Heating Up Again. Here's Which Ones Could be the Biggest Winners. ↗

June 01, 2026

The post-280E era will usher in new winners among cannabis stocks.

Via The Motley Fool

Topics Cannabis Earnings

Is Green Thumb Becoming the "Procter & Gamble of Cannabis"? ↗

May 25, 2026

Cannabis company Green Thumb is younger and in a different sector than consumer staples giant Procter & Gamble, but it's succeeding with similar methods.

Via The Motley Fool

Topics Cannabis

If You're a Long-Term Growth Investor, This Is the Sector to Be Focusing On, and It Has Nothing to Do With Artificial Intelligence ↗

May 25, 2026

The cannabis industry could be on the cusp of significant growth in the coming years.

Via The Motley Fool

Topics Artificial Intelligence Cannabis

2 Medical Marijuana Stocks to Buy Now ↗

May 03, 2026

Trulieve Cannabis and Green Thumb Industries are already two of the top cannabis retailers in the U.S. The Department of Justice reclassification makes them even stronger.

Via The Motley Fool

Topics Cannabis

New Cannabis Rules Just Created Winners and Losers: What the Split Schedule Means for Medical Operators and MSOs ↗

April 30, 2026

New cannabis rules boost medical-only profits while challenging multi-state operators.

Via The Motley Fool

Topics Cannabis

3 Cannabis Stocks That Could Soar After Marijuana Rescheduling ↗

April 28, 2026

These companies are major players in the U.S. marijuana market, and they all generated more than $1 billion in revenue last year.

Via The Motley Fool

Topics Cannabis

Marijuana Rescheduling Has Arrived. Don't Make This Mistake ↗

April 27, 2026

The Trump administration recently rescheduled medical marijuana from a Schedule I to Schedule III substance.

Via The Motley Fool

Topics Cannabis Government

The Cannabis Sector's Billion-Dollar Tax Cut ↗

April 23, 2026

Via MarketBeat

Topics Cannabis

Tilray Surges on Record Revenue and Global Expansion Despite Third-Quarter Earnings Miss

April 01, 2026

In a paradoxical display of market confidence, shares of Tilray Brands (NASDAQ:TLRY) surged over 8% on Wednesday following the release of its fiscal third-quarter 2026 financial results. While the...

Via MarketMinute

Topics Cannabis Earnings

The High Stakes of Reform: Canopy Growth Navigates a Volatile Regulatory Labyrinth in 2026

January 09, 2026

As of January 9, 2026, the cannabis sector finds itself at a historic crossroads, caught between the euphoria of federal progress and the harsh reality of market mechanics. Following a landmark...

Via MarketMinute

Topics Bankruptcy Cannabis ETFs

5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right ↗

January 04, 2026

Not all of these predictions may come true. But at least a few of them will likely do so.

Via The Motley Fool

Topics Artificial Intelligence Economy

Everything Investors Need to Know About President Trump's Executive Order Reclassifying Marijuana as a Lower Class of Drug ↗

December 23, 2025

President Donald Trump just signed an executive order that reclassified marijuana from a Schedule I narcotic to Schedule III.

Via The Motley Fool

Topics Cannabis Government

President Trump Just Reclassified Marijuana. Are Green Thumb, Tilray, and Trulieve Stocks No-Brainer Buys? ↗

December 23, 2025

These cannabis companies could soon see more green thanks to the president's milestone decision.

Via The Motley Fool

Topics Cannabis Government Law Enforcement

President Donald Trump Just Fast-Tracked the Rescheduling of Marijuana, and Pot Stocks Plunged -- Here's the Nefarious Reason Why ↗

December 22, 2025

Trump's historic executive order to reclassify cannabis isn't the victory it appears to be.

Via The Motley Fool

Topics Cannabis Government World Trade

The Green Resurgence: Tilray and Cannabis Sector Skyrocket Following Landmark Executive Action

December 19, 2025

The cannabis sector is experiencing a historic "Santa Claus rally" this December, with stock prices surging across the board following a transformative shift in federal policy. Today, December 19,...

Via MarketMinute

Topics Cannabis

Cannabis Sector Rocks Under Historic Trump Executive Order: Rescheduling Spark Ignites Market Volatility

December 19, 2025

In a move that has sent shockwaves through the global financial markets, the cannabis sector is currently navigating a period of unprecedented volatility following a landmark regulatory shift. On...

Via MarketMinute

Topics Cannabis ETFs Government

Cannabis Stocks Up for Reversal: Pipedreams or Opportunity? ↗

December 18, 2025

Via MarketBeat

Topics Cannabis

Why Trulieve Cannabis Skyrocketed 14.1% Today ↗

December 16, 2025

A shift in federal marijuana policy could be coming.

Via The Motley Fool

Topics Cannabis Government Stocks

Trump Moves A Step Closer To Reclassifying Marijuana As A Less Dangerous Drug — A Breakout Moment For Weed Industry? ↗

December 12, 2025

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

Via Stocktwits

Topics Cannabis Government

Tilray, IIPR, Trulieve, Other Cannabis Stocks Rally On Report Of Government Considering Adding CBD Treatment For Medicare Patients ↗

November 26, 2025

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare.

Via Stocktwits

Topics Cannabis ETFs Government

Why Investors Were High on Trulieve Cannabis Stock Today ↗

November 05, 2025

The weed purveyor's latest quarter featured a net loss, but it's been worse in the past.

Via The Motley Fool

Topics Cannabis

Why Trulieve Cannabis Stock Sank by 4% Today ↗

October 27, 2025

Congress is being lobbied to tighten regulations on hemp products throughout the U.S.

Via The Motley Fool

Topics Cannabis Law Enforcement

Tilray, Canopy Growth: Cannabis Stocks Lose High Premarket After Surge Triggered By Trump's Post ↗

September 30, 2025

Via Stocktwits

Topics Cannabis Government

If You'd Invested $1,000 in Trulieve Cannabis (TCNNF) 3 Years Ago, Here's How Much You'd Have Today ↗

August 13, 2025

This top pot stock feels like a solid contrarian play while the weed industry is generally down.

Via The Motley Fool

Topics Cannabis

Cannabis ETFs Light Up As Trump Eyes Marijuana Reclassification ↗

August 12, 2025

Cannabis stocks and ETFs skyrocketed after Trump hinted at reclassifying marijuana. Tilray surged 35% in 2 days. Other top performers included Trulieve, Tilray, Curaleaf, and Canopy Growth. This shift...

Via Benzinga

Topics Cannabis ETFs Government

Trump Confirms Marijuana Reclassification Decision To Be Made In ‘Next Few Weeks’ ↗

August 11, 2025

Via Stocktwits

Topics Cannabis Government

Retail Bulls Pile Into Cannabis Stocks On Reports Trump May Reclassify Marijuana; Traders Eye Aurora Rally ↗

August 11, 2025

Via Stocktwits

Topics Cannabis Government

Bearish Sentiment Across The Cannabis Space - Check Full Movers For July 11, 2025 ↗

July 11, 2025

Via Benzinga

Topics Cannabis

< Previous 1 2 3 4 5 6 7 8 9

...

44 45 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.